Remdesivir Drug Trial

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir Drug Trial - The Lancet [NCT04257656]

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Remdesivir Drug Trial - The New England Medical Journal [NCT04292899]

Remdesivir for 5 or 10 Days in Patients with severe Covid-19

Elsevier Biomedicine & Pharmacotherapy

Safety profile of the antiviral drug remdesivir: An update

Published 22 July 2020, the report says, “with increasing application, adverse effects of remdesivir have been detected and become a concern of clinicians. Since current safety data about remdesivir is fragmented and limited, we reviewed published studies and official documents regarding remdesivir treatment and summarize the up-to-date safety information, especially in COVID-19 patients, to provide evidence for clinical practices.”

The list of adverse events published in the report is provided below.

Remdesivir for the Treatment of Covid-19

New England Journal of Medicine [NCT04280705]

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19

JAMA - American Medical Association [NCT04292730]

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19

Annals of Internal Medicine [NCT04321616]

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, ramdomised, controlled, open-label trial